other compounds licensed from the Wisconsin Alumni Research Foundation. Deltanoid's continued focus is to develop selected therapies through early phases of the drug development process and seek partners for later stage development and commercialization in a wide variety of therapeutic areas, including renal disease, osteoporosis, and acne.

Currently Deltanoid has a partnership agreement in place with Novadiol, Inc. for development of a vitamin D therapy.